82 related articles for article (PubMed ID: 21976620)
1. Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes.
Cooke BR; Bligh SW; Cybulski ZR; Ioannides C; Hall M
Drug Metab Dispos; 2012 Jan; 40(1):70-5. PubMed ID: 21976620
[TBL] [Abstract][Full Text] [Related]
2. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
[TBL] [Abstract][Full Text] [Related]
3. Catalytic specificity of CYP2D isoforms in rat and human.
Hiroi T; Chow T; Imaoka S; Funae Y
Drug Metab Dispos; 2002 Sep; 30(9):970-6. PubMed ID: 12167561
[TBL] [Abstract][Full Text] [Related]
4. Interaction of plasma proteins with cytochromes P450 mediated metabolic reactions: inhibition by human serum albumin and alpha-globulins of the debrisoquine 4-hydroxylation (CYP2D) in liver microsomes of human, hamster and rat.
Ishii M; Xu BQ; Ding LR; Fischer NE; Inaba T
Toxicol Lett; 2001 Mar; 119(3):219-25. PubMed ID: 11246175
[TBL] [Abstract][Full Text] [Related]
5. Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling.
Lightfoot T; Ellis SW; Mahling J; Ackland MJ; Blaney FE; Bijloo GJ; De Groot MJ; Vermeulen NP; Blackburn GM; Lennard MS; Tucker GT
Xenobiotica; 2000 Mar; 30(3):219-33. PubMed ID: 10752638
[TBL] [Abstract][Full Text] [Related]
6. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
7. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling.
Wolff T; Distlerath LM; Worthington MT; Groopman JD; Hammons GJ; Kadlubar FF; Prough RA; Martin MV; Guengerich FP
Cancer Res; 1985 May; 45(5):2116-22. PubMed ID: 3921236
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin.
Jaruratanasirikul S; Cooper AD; Blaschke TF
Drug Metab Dispos; 1992; 20(3):379-82. PubMed ID: 1355711
[TBL] [Abstract][Full Text] [Related]
10. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
11. Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: comparison with the known marmoset CYP2D19.
Hichiya H; Kuramoto S; Yamamoto S; Shinoda S; Hanioka N; Narimatsu S; Asaoka K; Miyata A; Iwata S; Nomoto M; Satoh T; Kiryu K; Ueda N; Naito S; Tucker GT; Ellis SW
Biochem Pharmacol; 2004 Jul; 68(1):165-75. PubMed ID: 15183128
[TBL] [Abstract][Full Text] [Related]
12. 1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans.
Eiermann B; Edlund PO; Tjernberg A; Dalén P; Dahl ML; Bertilsson L
Drug Metab Dispos; 1998 Nov; 26(11):1096-101. PubMed ID: 9806952
[TBL] [Abstract][Full Text] [Related]
13. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
14. Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.
Kahn GC; Boobis AR; Murray S; Brodie MJ; Davies DS
Br J Clin Pharmacol; 1982 May; 13(5):637-45. PubMed ID: 7082530
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.
Distlerath LM; Guengerich FP
Proc Natl Acad Sci U S A; 1984 Dec; 81(23):7348-52. PubMed ID: 6594694
[TBL] [Abstract][Full Text] [Related]
16. Complementary DNA cloning, functional expression and characterization of a novel cytochrome P450, CYP2D50, from equine liver.
DiMaio Knych HK; Stanley SD
Biochem Pharmacol; 2008 Oct; 76(7):904-11. PubMed ID: 18692486
[TBL] [Abstract][Full Text] [Related]
17. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
[TBL] [Abstract][Full Text] [Related]
18. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
[TBL] [Abstract][Full Text] [Related]
19. Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity.
Wan J; Imaoka S; Chow T; Hiroi T; Yabusaki Y; Funae Y
Arch Biochem Biophys; 1997 Dec; 348(2):383-90. PubMed ID: 9434752
[TBL] [Abstract][Full Text] [Related]
20. Nafenopin-, ciprofibroyl-, and palmitoyl-CoA conjugation in vitro: kinetic and molecular characterization of marmoset liver microsomes and expressed MLCL1.
Drogemuller CJ; Nunthasomboon S; Knights KM
Arch Biochem Biophys; 2001 Dec; 396(1):56-64. PubMed ID: 11716462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
